Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy

Urology

Volumn 64, Issue 1, 2004, Pages 69-73

  Herman, Joseph M ^b   Smith, David C ^b   Montie, James ^b   Hayman, James A ^b   Sullivan, Molly A ^b   Kent, Elizabeth ^b   Griffith, Kent A ^b   Esper, Peggy ^b   Sandler, Howard M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ADULT; AGED; ALOPECIA; BLADDER CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; HUMAN; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 3042782476     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.02.024     Document Type: Article

References (26)

1. Gospodarowicz M. Radiotherapy and organ preservation in bladder cancer are we ignoring the evidence? J Clin Oncol. 20:2002;3048-3050
2. Kim H.L., Steinberg G.D. The current status of bladder preservation in the treatment of muscle invasive bladder cancer. J Urol. 164:2000;627-632
3. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer long-term results. J Clin Oncol. 20:2002;3061-3071
4. Kuczyk M., Turkeri L., Hammerer P., et al. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer? Eur Urol. 44:2003;57-64
5. Shipley W.U., Kaufman D.S., Tester W.J., et al. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer. 97:2003;2115-2119
6. Hussain S.A., James N.D. Organ preservation strategies in bladder cancer. Expert Rev Anticancer Ther. 2:2002;641-651
7. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 19:2001;4202-4208
8. Kuczyk M., Machtens S., Bokemeyer C., et al. Surgical bladder preserving strategies in the treatment of muscle-invasive bladder cancer. World J Urol. 20:2002;183-189
9. Webster K, Cella D, Yost K: The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 1: 79-85, 2003
10. Botteman M.F., Pashos C.L., Hauser R.S., et al. Quality of life aspects of bladder cancer a review of the literature. Qual Life Res. 12:2003;675-688
11. Verbeke G., Molenberghs G. Linear Mixed Models in Practice A SAS-Oriented Approach. 1997;Springer, New York
12. Cella D., Eton D.T., Fairclough D.L., et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592. J Clin Epidemiol. 55:2002;285-295
13. Cella D., Hahn E.A., Dineen K. Meaningful change in cancer-specific quality of life scores differences between improvement and worsening. Qual Life Res. 11:2002;207-221
14. Shipley W.U., Kaufman D.S., Heney N.M., et al. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol. 162:1999;445-451
15. Scher H., Herr H., Sternberg C., et al. M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation. Prog Clin Biol Res. 353:1990;179-186
16. Kachnic L.A., Kaufman D.S., Heney N.M., et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 15:1997;1022-1029
17. Eisbruch A., Shewach D.S., Bradford C.R., et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer a phase I trial and intracellular drug incorporation study. J Clin Oncol. 19:2001;792-799
18. Blackstock A.W., Melin S.A., Butler J.M., et al. Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer. Oncology (Huntingt). 16:2002;25-28
19. Albers P., Siener R., Hartlein M., et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie. 25:2002;47-52
20. Kent E, Montie J, Lee C, et al. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol (in press)
21. Clark J.A., Bokhour B.G., Inui T.S., et al. Measuring patients' perceptions of the outcomes of treatment for early prostate cancer. Med Care. 41:2003;923-936
22. Hardt J., Filipas D., Hohenfellner R., et al. Quality of life in patients with bladder carcinoma after cystectomy first results of a prospective study. Qual Life Res. 9:2000;1-12
23. Zietman A.L., Sacco D., Skowronski U., et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation results of a urodynamic and quality of life study on long-term survivors. J Urol. 170:2003;1772-1776
24. Dunst J., Rodel C., Zietman A., et al. Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol. 20:2001;24-32
25. Miyanaga N, Akaza H, Shinohara N, et al. [Assessment of QOL and survival for patients undergoing radical cystectomy or bladder preservation for invasive bladder cancer]. Nippon Hinyokika Gakkai Zasshi 90: 445-453, 1999
26. Cookson M.S., Dutta S.C., Chang S.S., et al. Health related quality of life in patients treated with radical cystectomy and urinary diversion for urothelial carcinoma of the bladder development and validation of a new disease specific questionnaire. J Urol. 170:2003;1926-1930